ALK-positive NSCLC peptide vaccine

· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALK-positive NSCLC peptide vaccine, covering 2025-09-23 to 2025-09-23. Get the full timeline:

Most recent: Clinical Trial Update: Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC [Phase 1, Phase 2]